The global human chorionic gonadotropin (HCG) market size reached US$ 973.5 million in 2023. The market is projected to reach US$ 1,768.4 million by 2032, exhibiting a growth rate (CAGR) of 6.86% during 2023-2032. The rising incidences of infertility in women, increasing prevalence of hypogonadism-related disorders, and production of HCG using recombinant technology represent some of the key factors driving the market.
Human chorionic gonadotropin (HCG) is a chemical produced by syncytiotrophoblastic cells of the placenta during pregnancy. It is found in blood, urine, liver, colon, and pituitary glands. HCG stimulates the corpus luteum to produce progesterone to maintain the pregnancy. It is extracted and purified from the urine of pregnant women for clinical applications using various techniques, such as ion exchange chromatography, dye-affinity chromatography, nanofiltration, and reverse-phase high-performance liquid chromatography (HPLC). HCG is widely used to treat infertility, increase the chances of pregnancy, help in the production of testosterone and sperm, and treat cryptorchidism in male children. It also aids in diagnosing and monitoring pregnancy-related disorders, prenatal screening, and gynecological cancers.
Human chorionic gonadotropin (HCG) is a chemical produced by syncytiotrophoblastic cells of the placenta during pregnancy. It is found in blood, urine, liver, colon, and pituitary glands. HCG stimulates the corpus luteum to produce progesterone to maintain the pregnancy. It is extracted and purified from the urine of pregnant women for clinical applications using various techniques, such as ion exchange chromatography, dye-affinity chromatography, nanofiltration, and reverse-phase high-performance liquid chromatography (HPLC). HCG is widely used to treat infertility, increase the chances of pregnancy, help in the production of testosterone and sperm, and treat cryptorchidism in male children. It also aids in diagnosing and monitoring pregnancy-related disorders, prenatal screening, and gynecological cancers.
Human Chorionic Gonadotropin (HCG) Market Trends
The rising incidences of infertility among females due to uterine disorders, blocked fallopian tube, polycystic ovarian syndrome (PCOS), and endocrine system disorders are among the key factors driving the market growth. HCG is widely used in various assisted reproductive technologies, such as in-vitro fertilization (IVF) and intrauterine insemination (IUI), to treat female infertility, as it aids in inducing ovulation, promotes the formation of the embryo, facilitates correct timing of oocyte retrieval, increases endometrial thickness, and improve endometrial receptivity. In addition to this, the widespread product utilization in combination with other fertility drugs to increase the chances of pregnancy in women is acting as another growth-inducing factor. Furthermore, the increasing application of HCG to improve testosterone levels, enhance fertility, and promote sexual function due to the increasing prevalence of hypogonadism-related disorders in males suffering from obesity and type 2 diabetes is favoring the market growth. Additionally, the production of HCG using recombinant technology that provides identical properties, enhanced efficacy, and improved safety compared to naturally sourced HCG and enhances patient tolerance is positively influencing the market growth. Other factors, including the rapid development of healthcare infrastructure, increasing availability of treatment and services regarding infertility, rising geriatric population, extensive research and development (R&D) activities for the launch of novel purification and extraction technologies, and the implementation of various government initiatives to improve the sexual health of people, are anticipated to drive the market growth further.Key Market Segmentation:
The report provides an analysis of the key trends in each segment of the global human chorionic gonadotropin (HCG) market, along with forecasts at the global, regional, and country level from 2023-2032. The report has categorized the market based on technology, therapeutic area, and end user.Technology Insights:
- Natural Source Extraction
- Recombinant Technology
Therapeutic Area Insights:
- Female Infertility Treatment
- Male Hypogonadism
- Oligospermic Treatment
- Others
End User Insights:
- Fertility Clinics
- Research Institutions
- Others
Regional Insights:
- North America
- United States
- Canada
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Competitive Landscape
The report has also provided a comprehensive analysis of the competitive landscape in the global human chorionic gonadotropin (HCG) market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Biocare Medical LLC, Ferring Pharmaceuticals, Fresenius SE & Co. KGaA, Kamiya Biomedical Company (Nitto Boseki Co. Ltd.), Lee Biosolutions Inc. (Oy Medix Biochemica Ab), Merck & Co. Inc., Prospec-Tany Technogene Ltd., Scripps Laboratories Inc., Sun Pharmaceutical Industries Limited, etc.Key Questions Answered in This Report:
- How has the global human chorionic gonadotropin (HCG) market performed so far and how will it perform in the coming years?
- What are the drivers, restraints, and opportunities in the global human chorionic gonadotropin (HCG) market?
- What are the key regional markets?
- Which countries represent the most attractive human chorionic gonadotropin (HCG) markets?
- What is the breakup of the market based on the technology?
- What is the breakup of the market based on the therapeutic area?
- What is the breakup of the market based on the end user?
- What is the competitive structure of the global human chorionic gonadotropin (HCG) market?
- Who are the key players/companies in the global human chorionic gonadotropin (HCG) market?
Table of Contents
1 Preface3 Executive Summary11 Value Chain Analysis13 Price Analysis
2 Scope and Methodology
4 Introduction
5 Global Human Chorionic Gonadotropin (HCG) Market
6 Market Breakup by Technology
7 Market Breakup by Therapeutic Area
8 Market Breakup by End User
9 Market Breakup by Region
10 Drivers, Restraints, and Opportunities
12 Porters Five Forces Analysis
14 Competitive Landscape
List of Figures
List of Tables
Companies Mentioned
- Biocare Medical LLC
- Ferring Pharmaceuticals
- Fresenius SE & Co. KGaA
- Kamiya Biomedical Company (Nitto Boseki Co. Ltd.)
- Lee Biosolutions Inc. (Oy Medix Biochemica Ab)
- Merck & Co. Inc.
- Prospec-Tany Technogene Ltd.
- Scripps Laboratories Inc.
- Sun Pharmaceutical Industries Limited
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 139 |
| Published | January 2024 |
| Forecast Period | 2023 - 2032 |
| Estimated Market Value ( USD | $ 973.5 Million |
| Forecasted Market Value ( USD | $ 1768 Million |
| Compound Annual Growth Rate | 6.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 9 |
